



Media Contact:
Melissa Neill
Java Culture Agency
(651) 295-6761

melissa@javacultureagency.com

Long Grove Pharmaceuticals Receives FDA Approval for Generic Edaravone Injection

Ready-to-use premix expands treatment options for Amyotrophic Lateral Sclerosis

ROSEMONT, Ill.— May 7, 2024 — Long Grove Pharmaceuticals, LLC, a supplier of differentiated pharmaceuticals, has received Food and Drug Administration (FDA) approval for generic Edaravone Injection. Edaravone Injection adds to the company’s growing portfolio of products that improve patient access to pharmaceuticals.

Edaravone Injection is an AP-rated medication bioequivalent to RADICAVA® IV and is used to treat amyotrophic lateral sclerosis (ALS). The FDA approved RADICAVA in 2017, making it the first new treatment for ALS in more than 20 years. Edaravone targets and helps remove free radicals to reduce nerve damage and slow the progression of ALS, a neurodegenerative disease.

“Currently, a generic equivalent for Edaravone Injection is not commercially available,” said Peter Karas, Chief Commercial Officer of Long Grove Pharmaceuticals. “A generic increases the number of patients who can benefit from this critical ALS treatment option, and we’re grateful for the opportunity to help expand access.”

Long Grove Pharmaceuticals received FDA approval for the drug through the Abbreviated New Drug Application (ANDA) pathway. The company’s Edaravone Injection comes in a ready-to-use premix formulation with two 30 mg/100 mL bags per carton. The formulation is stable at room temperature and the IV bags are not made with natural rubber latex, DEHP or PVC.

For more information about Long Grove Pharmaceuticals, visit www.longgrovepharma.com.

###

About Long Grove Pharmaceuticals

Long Grove Pharmaceuticals, LLC was established in 2019 by Water Street Healthcare Partners. The company is part of Capstone Development Services, LLC, which has been developing products in partnership with the world’s premier pharmaceutical and medical device organizations since 2013. Combining decades of pharmaceutical and hospital leadership experience with a portfolio of specialized, complex drug formulations, Long Grove Pharmaceuticals is delivering differentiated products that increase hospital pharmacy operational efficiency and help improve the quality of patient care.